AKBA
Akebia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.97
−0.87%Margins
Gross margin
79.5%
EBITDA margin
-8.2%
EBIT margin
-6.9%
Net margin
-13.5%
FCF margin
18.4%
-118.6%
Return on equity
-8.5%
Return on assets
-19.2%
Return on invested capital
0.62x
Asset turnover
$41.6M
Cash from operations
$0.56
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026